CoChat

Overexpression of alpha synuclein disrupts APP and Endolysosomal axonal trafficking in a mouse model of synucleinopathy

Lin, Suzhen, Leitão, André D.G., Fang, Savannah, Gu, Yingli, Barber, Sophia, Gilliard-Telefoni, Rhiannon, Castro, Alfredo, Sung, Kijung, Shen, Ruinan, Florio, Jazmin B., Mante, Michael L., Ding, Jianqing, Spencer, Brian, Masliah, Eliezer, Rissman, Robert A., Wu, Chengbiao · 2023 · Neurobiology of Disease
Cited by 17

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.nbd.2023.106010

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

2 retracted

Research works printed but not linked: 81

  1. Araki, 2019, Parkinson’s disease is a type of amyloidosis featuring accumulation of amyloid fibrils of α-synuclein, Proc. Natl. Acad. Sci., 116, 17963, 10.1073/pnas.1906124116 · DOI
  2. Bachhuber, 2015, Inhibition of amyloid-β plaque formation by α-synuclein, Nat. Med., 21, 802, 10.1038/nm.3885 · DOI
  3. Berge, 2016, Alpha-synuclein measured in cerebrospinal fluid from patients with Alzheimer’s disease, mild cognitive impairment, or healthy controls: a two year follow-up study, BMC Neurol., 16, 1, 10.1186/s12883-016-0706-0 · DOI · Paper page
  4. Blumenstock, 2017, Seeding and transgenic overexpression of alpha-synuclein triggers dendritic spine pathology in the neocortex, EMBO Molecular Medicine, 9, 716, 10.15252/emmm.201607305 · DOI
  5. Boassa, 2013, Mapping the subcellular distribution of α-synuclein in neurons using genetically encoded probes for correlated light and electron microscopy: implications for Parkinson’s disease pathogenesis, J. Neurosci., 33, 2605, 10.1523/JNEUROSCI.2898-12.2013 · DOI
  6. Burré, 2010, α-Synuclein promotes SNARE-complex assembly in vivo and in vitro, Science, 329, 1663, 10.1126/science.1195227 · DOI · Paper page
  7. Burré, 2014, α-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation, Proc. Natl. Acad. Sci., 111, E4274, 10.1073/pnas.1416598111 · DOI · Paper page
  8. Carnazza, 2022, Synaptic vesicle binding of α-synuclein is modulated by β-and γ-synucleins, Cell Rep., 39, 10.1016/j.celrep.2022.110675 · DOI
  9. Carnwath, 2018, The direct and indirect effects of α-synuclein on microtubule stability in the pathogenesis of Parkinson’s disease, Neuropsychiatr. Dis. Treat., 14, 1685, 10.2147/NDT.S166322 · DOI
  10. Caviston, 2007, Huntingtin facilitates dynein/dynactin-mediated vesicle transport, Proceedings of the National Academy of Sciences, 104, 10045, 10.1073/pnas.0610628104 · DOI · Paper page
  11. Chassefeyre, 2021, Endosomal sorting drives the formation of axonal prion protein endoggresomes, Sci. Adv., 7, eabg3693, 10.1126/sciadv.abg3693 · DOI
  12. Chen, 1995, The human NACP/α-synuclein gene: chromosome assignment to 4q21. 3–q22 and TaqI RFLP analysis, Genomics, 26, 425, 10.1016/0888-7543(95)80237-G · DOI
  13. Chu, 2012, Alterations in axonal transport motor proteins in sporadic and experimental Parkinson’s disease, Brain, 135, 2058, 10.1093/brain/aws133 · DOI · Paper page
  14. Crews, 2009, Role of synucleins in Alzheimer’s disease, Neurotox. Res., 16, 306, 10.1007/s12640-009-9073-6 · DOI
  15. Das, 2013, Activity-induced convergence of APP and BACE-1 in acidic microdomains via an endocytosis-dependent pathway, Neuron, 79, 447, 10.1016/j.neuron.2013.05.035 · DOI · Paper page
  16. Devi, 2010, Mitochondrial trafficking of APP and alpha synuclein: relevance to mitochondrial dysfunction in Alzheimer’s and Parkinson’s diseases, Biochim. Biophys. Acta, 1802, 11, 10.1016/j.bbadis.2009.07.007 · DOI
  17. Diao, 2013, Native α-synuclein induces clustering of synaptic-vesicle mimics via binding to phospholipids and synaptobrevin-2/VAMP2, elife, 2, 10.7554/eLife.00592 · DOI · Paper page
  18. Duce, 2010, Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer's disease, Cell, 142, 857, 10.1016/j.cell.2010.08.014 · DOI · Paper page
  19. Fakhree, 2021, The localization of alpha-synuclein in the endocytic pathway, Neuroscience, 457, 186, 10.1016/j.neuroscience.2021.01.017 · DOI
  20. Fang, 2017, Synuclein impairs trafficking and signaling of BDNF in a mouse model of Parkinson’s disease, Sci. Rep., 7, 1
  21. Ferman, 2018, The limbic and neocortical contribution of α-synuclein, tau, and amyloid β to disease duration in dementia with Lewy bodies, Alzheimers Dement., 14, 330, 10.1016/j.jalz.2017.09.014 · DOI
  22. Froula, 2018, α-Synuclein fibril-induced paradoxical structural and functional defects in hippocampal neurons, Acta Neuropathologica Communications, 6, 1, 10.1186/s40478-018-0537-x · DOI · Paper page
  23. Galvin, 1999, Axon pathology in Parkinson’s disease and Lewy body dementia hippocampus contains α-, β-, and γ-synuclein, Proc. Natl. Acad. Sci., 96, 13450, 10.1073/pnas.96.23.13450 · DOI · Paper page
  24. Gao, 2018, The emerging role of Rab GTPases in the pathogenesis of Parkinson’s disease, Mov. Disord., 33, 196, 10.1002/mds.27270 · DOI
  25. Gonçalves, 2017, Traffic jams and the complex role of α-Synuclein aggregation in Parkinson disease, Small GTPases, 8, 78, 10.1080/21541248.2016.1199191 · DOI
  26. Gonçalves, 2016, shRNA-based screen identifies endocytic recycling pathway components that act as genetic modifiers of alpha-synuclein aggregation, secretion and toxicity, PLoS Genet., 12, 10.1371/journal.pgen.1005995 · DOI
  27. Hamilton, 2000, Lewy bodies in Alzheimer’s disease: a neuropathological review of 145 cases using α-synuclein immunohistochemistry, Brain Pathol., 10, 378, 10.1111/j.1750-3639.2000.tb00269.x · DOI · Paper page
  28. Hansen, 2013, A novel α-synuclein-GFP mouse model displays progressive motor impairment, olfactory dysfunction and accumulation of α-synuclein-GFP, Neurobiol. Dis., 56, 145, 10.1016/j.nbd.2013.04.017 · DOI
  29. Hansen, 1993, Plaque-only Alzheimer disease is usually the Lewy body variant, and vice versa, J. Neuropathol. Exp. Neurol., 52, 648, 10.1097/00005072-199311000-00012 · DOI · Paper page
  30. Houlden, 2012, The genetics and neuropathology of Parkinson’s disease, Acta Neuropathol., 124, 325, 10.1007/s00401-012-1013-5 · DOI · Paper page
  31. Hu, 2015, The endosomal-lysosomal system: from acidification and cargo sorting to neurodegeneration, Translational Neurodegeneration, 4, 1, 10.1186/s40035-015-0041-1 · DOI · Paper page
  32. Hunn, 2015, Impaired intracellular trafficking defines early Parkinson’s disease, Trends Neurosci., 38, 178, 10.1016/j.tins.2014.12.009 · DOI · Paper page
  33. Iwai, 1996, The synaptic protein NACP is abnormally expressed during the progression of Alzheimer’s disease, Brain Res., 720, 230, 10.1016/0006-8993(96)00014-5 · DOI
  34. Jellinger, 2011, Interaction between ?-Synuclein and other proteins in neurodegenerative disorders, TheScientificWorldJournal, 11, 1893, 10.1100/2011/371893 · DOI
  35. Kang, 2017, TrkB neurotrophic activities are blocked by α-synuclein, triggering dopaminergic cell death in Parkinson’s disease, Proc. Natl. Acad. Sci., 114, 10773, 10.1073/pnas.1713969114 · DOI · Paper page
  36. Kaul, 2011, Region-specific tauopathy and synucleinopathy in brain of the alpha-synuclein overexpressing mouse model of Parkinson’s disease, BMC Neurosci., 12, 1, 10.1186/1471-2202-12-79 · DOI
  37. Kim, 2016, Evidence that the rab5 effector APPL1 mediates APP-βCTF-induced dysfunction of endosomes in down syndrome and Alzheimer’s disease, Mol. Psychiatry, 21, 707, 10.1038/mp.2015.97 · DOI · Paper page
  38. Kim, 2021, Dysregulation of mitochondria-lysosome contacts by GBA1 dysfunction in dopaminergic neuronal models of Parkinson’s disease, Nat. Commun., 12, 1
  39. Kwart, 2019, A large panel of isogenic APP and PSEN1 mutant human iPSC neurons reveals shared endosomal abnormalities mediated by APP β-CTFs, not Aβ, Neuron, 104
  40. Leitão, 2021, Selectivity of Lewy body protein interactions along the aggregation pathway of α-synuclein, Commun Biol, 4, 1124, 10.1038/s42003-021-02624-x · DOI
  41. Majbour, 2017, Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer’s disease, Sci. Rep., 7, 1, 10.1038/srep40263 · DOI · Paper page
  42. Maroteaux, 1988, Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal, J. Neurosci., 8, 2804, 10.1523/JNEUROSCI.08-08-02804.1988 · DOI · Paper page
  43. Marui, 2000, Occurrence of human α-synuclein immunoreactive neurons with neurofibrillary tangle formation in the limbic areas of patients with Alzheimer’s disease, J. Neurol. Sci., 174, 81, 10.1016/S0022-510X(99)00327-5 · DOI
  44. Masaracchia, 2018, Membrane binding, internalization, and sorting of alpha-synuclein in the cell, Acta Neuropathologica Communications, 6, 1, 10.1186/s40478-018-0578-1 · DOI
  45. Mazzulli, 2016, α-Synuclein–induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models, Proc. Natl. Acad. Sci., 113, 1931, 10.1073/pnas.1520335113 · DOI · Paper page
  46. Mikolaenko, 2005, Alpha-synuclein lesions in normal aging, Parkinson disease, and Alzheimer disease: evidence from the Baltimore longitudinal study of aging (BLSA), J. Neuropathol. Exp. Neurol., 64, 156, 10.1093/jnen/64.2.156 · DOI · Paper page
  47. Mullin, 2015, The genetics of Parkinson’s disease, Br. Med. Bull., 114, 39, 10.1093/bmb/ldv022 · DOI
  48. Navarro-Romero, 2020, The emerging role of the lysosome in Parkinson’s disease, Cells, 9, 2399, 10.3390/cells9112399 · DOI
  49. Ono, 2012, Cross-seeding effects of amyloid β-protein and α-synuclein, J. Neurochem., 122, 883, 10.1111/j.1471-4159.2012.07847.x · DOI · Paper page
  50. Osterberg, 2015, Progressive aggregation of alpha-synuclein and selective degeneration of lewy inclusion-bearing neurons in a mouse model of parkinsonism, Cell Rep., 10, 1252, 10.1016/j.celrep.2015.01.060 · DOI · Paper page
  51. Overk, 2014, Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5–implications for dementia with Lewy bodies, Mol. Neurodegener., 9, 1, 10.1186/1750-1326-9-18 · DOI
  52. Pensalfini, 2020, Endosomal dysfunction induced by directly overactivating Rab5 recapitulates prodromal and neurodegenerative features of Alzheimer’s disease, Cell Rep., 33, 10.1016/j.celrep.2020.108420 · DOI
  53. Price, 2016, Longitudinal live imaging of retinal α-synuclein:: GFP deposits in a transgenic mouse model of Parkinson’s Disease/Dementia with Lewy Bodies, Sci. Rep., 6, 1, 10.1038/srep29523 · DOI
  54. Price, 2018, The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson’s disease, Sci. Rep., 8, 1, 10.1038/s41598-018-34490-9 · DOI · Paper page
  55. Roberts, 2017, α-Synuclein increases β-amyloid secretion by promoting β−/γ-secretase processing of APP, PLoS One, 12, 10.1371/journal.pone.0171925 · DOI
  56. Rockenstein, 2005, Lysosomal pathology associated with α-synuclein accumulation in transgenic models using an eGFP fusion protein, J. Neurosci. Res., 80, 247, 10.1002/jnr.20446 · DOI
  57. Rodrigues, 2012, Enhanced β-secretase processing alters APP axonal transport and leads to axonal defects, Hum. Mol. Genet., 21, 4587, 10.1093/hmg/dds297 · DOI · Paper page
  58. Sahin, 2006, The distribution pattern of pathology and cholinergic deficits in amygdaloid complex in Alzheimer’s disease and dementia with Lewy bodies, Acta Neuropathol., 111, 115, 10.1007/s00401-005-0003-2 · DOI
  59. Schützmann, 2021, Endo-lysosomal Aβ concentration and pH trigger formation of Aβ oligomers that potently induce tau missorting, Nat. Commun., 12, 1, 10.1038/s41467-021-24900-4 · DOI · Paper page
  60. Scott, 2010, A pathologic cascade leading to synaptic dysfunction in α-synuclein-induced neurodegeneration, J. Neurosci., 30, 8083, 10.1523/JNEUROSCI.1091-10.2010 · DOI · Paper page
  61. Shen, 2018, Dynactin is involved in Lewy body pathology, Neuropathology, 38, 583, 10.1111/neup.12512 · DOI
  62. Shen, 2020, Upregulation of RIN3 induces endosomal dysfunction in Alzheimer’s disease, Translational Neurodegeneration, 9, 1, 10.1186/s40035-020-00206-1 · DOI
  63. Sheng, 2012, Mitochondrial transport in neurons: impact on synaptic homeostasis and neurodegeneration, Nat. Rev. Neurosci., 13, 77, 10.1038/nrn3156 · DOI · Paper page
  64. Shi, 2017, Rab GTPases: the key players in the molecular pathway of Parkinson’s disease, Front. Cell. Neurosci., 11, 81, 10.3389/fncel.2017.00081 · DOI
  65. Soper, 2011, Aggregation of α-synuclein in S. cerevisiae is associated with defects in endosomal trafficking and phospholipid biosynthesis, J. Mol. Neurosci., 43, 391, 10.1007/s12031-010-9455-5 · DOI
  66. Spencer, 2016, Reducing endogenous α-synuclein mitigates the degeneration of selective neuronal populations in an Alzheimer’s disease transgenic mouse model, J. Neurosci., 36, 7971, 10.1523/JNEUROSCI.0775-16.2016 · DOI · Paper page
  67. Spencer, 2019, Systemic peptide mediated delivery of an siRNA targeting α-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy body disease, Neurobiol. Dis., 127, 163, 10.1016/j.nbd.2019.03.001 · DOI
  68. Spinelli, 2014, Presynaptic alpha-synuclein aggregation in a mouse model of Parkinson’s disease, J. Neurosci., 34, 2037, 10.1523/JNEUROSCI.2581-13.2014 · DOI
  69. Stokin, 2005, Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease, Science, 307, 1282, 10.1126/science.1105681 · DOI · Paper page
  70. Taguchi, 2019, Expression of α-synuclein is regulated in a neuronal cell type-dependent manner, Anat. Sci. Int., 94, 11, 10.1007/s12565-018-0464-8 · DOI
  71. Teixeira, 2021, Alpha-Synuclein and the endolysosomal system in parkinson’s disease: guilty by association, Biomolecules, 11, 1333, 10.3390/biom11091333 · DOI
  72. Twohig, 2019, α-Synuclein in the pathophysiology of Alzheimer’s disease, Mol. Neurodegener., 14, 23, 10.1186/s13024-019-0320-x · DOI · Paper page
  73. Vingtdeux, 2007, Intracellular pH regulates amyloid precursor protein intracellular domain accumulation, Neurobiol. Dis., 25, 686, 10.1016/j.nbd.2006.09.019 · DOI
  74. Volpicelli-Daley, 2011, Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death, Neuron, 72, 57, 10.1016/j.neuron.2011.08.033 · DOI · Paper page
  75. Volpicelli-Daley, 2014, Formation of α-synuclein Lewy neurite–like aggregates in axons impedes the transport of distinct endosomes, Mol. Biol. Cell, 25, 4010, 10.1091/mbc.e14-02-0741 · DOI · Paper page
  76. Xu, 2016, Amyloid precursor protein–mediated endocytic pathway disruption induces axonal dysfunction and neurodegeneration, J. Clin. Invest., 126, 1815, 10.1172/JCI82409 · DOI · Paper page
  77. Xu, 2018, Dysregulation of Rab5-mediated endocytic pathways in Alzheimer's disease, Traffic, 19, 253, 10.1111/tra.12547 · DOI
  78. Yan, 2014, Overexpression of human E46K mutant α-synuclein impairs macroautophagy via inactivation of JNK1-Bcl-2 pathway, Mol. Neurobiol., 50, 685, 10.1007/s12035-014-8738-1 · DOI
  79. Yim, 2015, The multivesicular body is the major internal site of prion conversion, J. Cell Sci., 128, 1434, 10.1242/jcs.165472 · DOI
  80. Zhang, 2013, Defective axonal transport of Rab7 GTPase results in dysregulated trophic signaling, J. Neurosci., 33, 7451, 10.1523/JNEUROSCI.4322-12.2013 · DOI · Paper page
  81. Zhao, 2016, TRiC subunits enhance BDNF axonal transport and rescue striatal atrophy in Huntington’s disease, Proc. Natl. Acad. Sci., 113, E5655, 10.1073/pnas.1603020113 · DOI

Metadata

Authors
Lin, S., Leitão, A. D. G., Fang, S., Gu, Y., Barber, S., Gilliard-Telefoni, R., Castro, A., Sung, K., Shen, R., Florio, J. B., Mante, M. L., Ding, J., Spencer, B., Masliah, E., Rissman, R. A., & Wu, C.
Venue
Neurobiology of Disease
Publisher
Elsevier BV
Published
2023-03
Volume
178
Pages
106010
ISSN
0969-9961
Cited by
17
References
20
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.